U. S. Securities and Exchange Commission Washington, D. C. 20549

FORM 10-Q

☑ QUARTERLY REPORT U	JNDER SECTION 13 OR 15(d) OF THE SECU	URITIES EXCHANGE ACT OF 1934	
	For the quarterly period ended June 30, 20	022	
☐ TRANSITION REPORT U	JNDER SECTION 13 OR 15(d) OF THE SECU	URITIES EXCHANGE ACT OF 1934	
	For the transition period from to		
	Commission File No. 001-37370		
	MY SIZE, INC.		
	(Exact name of registrant as specified in its c	charter)	
Delaware		51-0394637	
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer I.D. No.)	
	HaYarden 4, POB 1026, Airport City, Israel, 7 (Address of principal executive offices		
	+972-3-600-9030 Registrant's telephone number, including area	a code:	
Securities registered pursuant to Section 12(b) of the Act:			
Title of each class	Trading Symbol(s)	Name of each exchange on whi	
Common Stock, \$0.001 par value per share	MYSZ	Nasdaq Capital Mark	tet
Indicate by check mark whether the registrant (1) has filed a 12 months (or for such shorter period that the registrant was			
Indicate by check mark whether the registrant has submitte 232.405 of this chapter) during the preceding 12 months (or		•	405 of Regulation S-T (§
Indicate by check mark whether the registrant is a large a company. See the definitions of "large accelerated filer," "ac			
Large accelerated filer □ Non-accelerated filer ⊠		Accelerated filer Smaller reporting company Emerging growth company	
If an emerging growth company, indicate by check mark if accounting standards provided pursuant to Section 13(a) of the standards provided pursuant to Section 13(b) of the standards provided pursuant to Section 13(b) of the standards provided pursuant to Section 13(b) of the standards provided pursuant to Section 13(c) of the standards provided pursuant to Section 13(c) of the standards provided pursuant to Section 13(d) of the standards pursuant to Section 1		led transition period for complying with an	y new or revised financial
Indicate by check mark whether the registrant is a shell comp	pany (as defined in Rule 12b-2 of the Exchange	e Act) Yes □ No ⊠	
Indicate the number of shares outstanding of each of the issu stock, par value \$0.001 per share were issued and outstanding		practicable date: as of August 8, 2022, 25,5	51,906 shares of common

MY SIZE, INC. INDEX TO QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2022

TABLE OF CONTENTS

		PAGE
PART I - FINA	NCIAL INFORMATION	1
Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)	2
	Condensed Consolidated Interim Balance Sheets	3
	Condensed Consolidated Interim Statements of Comprehensive Loss	4
	Condensed Consolidated Interim Statements of Changes in Stockholders' Equity	5
	Condensed Consolidated Interim Statements of Cash Flows	6
	Notes to Condensed Consolidated Interim Financial Statements	7-17
Item 2.	Management's Discussion & Analysis of Financial Condition and Results of Operations	18-22
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	23
Item 4.	Controls and Procedures	23
PART II - OTH	IER INFORMATION	24
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	25
Item 3.	<u>Defaults Upon Senior Securities</u>	25
Item 4.	Mine Safety Disclosures	25
Item 5	Other information	25
Item 6.	Exhibits	26
	i	

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

My Size Inc. and Subsidiaries

Condensed Consolidated Interim Financial Statements As of June 30, 2022 (unaudited) U.S. Dollars in Thousands

1

MY SIZE, INC. AND ITS SUBSIDIARIES

Condensed Consolidated Interim Financial Statements as of June 30, 2022 (Unaudited)

Contents	
	Page
Condensed Consolidated Interim Balance Sheets (Unaudited)	3
Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited)	4
Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)	5
Condensed Consolidated Interim Statements of Cash flows (Unaudited)	6
Notes to Condensed Consolidated Interim Financial Statements (Unaudited)	7-17
2	

	June 30, 2022	December 31, 2021
_	(Unaudited)	(Audited)
Assets		
Current Assets:		
Cash and cash equivalents	6,462	10,670
Restricted cash	263	273
Inventory, net	1,223	-
Accounts receivable	175	40
Other receivables and prepaid expenses	955	579
Total current assets	9,078	11,562
Long term deposit	29	-
Property and equipment, net	153	112
Right-of-use asset	715	776
Intangible asset	326	-
Goodwill	268	-
Investment in marketable securities	97	108
Total non-current assets	1,588	996
Total assets	10.666	12.550
10141 455015	10,666	12,558
Liabilities and stockholders' equity		
Current liabilities:		
Account payables	883	453
Right of use liability	173	138
Bank overdraft and short-term loans	178	-
Trade payables	950	635
Other payables	159	-
Derivatives	39	2
Total current liabilities	2,382	1,228
Long term loans	97	-
Deferred tax liabilities	75	-
Long term right of use liability	417	473
Total non-current liabilities	589	473
Total liabilities	2.071	1.701
1 otal nabilities	2,971	1,701
COMMITMENTS AND CONTINGENCIES		
Stockholders' equity:		
Stock Capital -		
Common stock of \$0.001 par value - Authorized: 200,000,000 shares; Issued and outstanding: 25,551,906	26	24
and 23,982,503 as of June 30, 2022 and December 31, 2021, respectively	57,048	56,430
Additional paid-in capital Accumulated other comprehensive loss		
Accumulated other comprehensive loss Accumulated deficit	(284)	(406)
_	(49,095)	(45,191)
Total stockholders' equity	7,695	10,857
Total liabilities and stockholders' equity	10,666	12,558

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

	Six-Months Ended June 30,		Three-Month June 3	
	2022	2021	2022	2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Revenues	1,205	57	801	30
Cost of revenues	(730)	<u> </u>	(479)	<u>-</u>
Gross profit	475	57	322	30
Operating expenses				
Research and development	(802)	(3,380)	(390)	(3,007)
Sales and marketing	(1,854)	(1,277)	(895)	(731)
General and administrative	(1,576)	(1,229)	(689)	(605)
Total operating expenses	(4,232)	(5,886)	(1,974)	(4,343)
Operating loss	(3,757)	(5,829)	(1,652)	(4,313)
Financial income (expenses), net	(147)	32	(64)	(27)
Net loss	(3,904)	(5,797)	(1,716)	(4,340)
Other comprehensive income (loss):				
Foreign currency translation differences	122	(16)	64	22
Total comprehensive loss	(3,782)	(5,813)	(1,652)	(4,318)
Basic and diluted loss per share	(0.16)	(0.51)	(0.07)	(0.33)
Basic and diluted weighted average number of shares outstanding	25,128,003	11,276,238	25,463,759	13,340,164

The accompanying notes are an integral part of the interim condensed consolidated financial statements

	Commo	n stock	Additional paid-in	Accumulated other comprehensive	Accumulated	Total stockholders'
	Number	Amount	capital	loss	deficit	equity
Balance as of January 1, 2022	23,982,503	24	56,430	(406)	(45,191)	10,857
Stock-based compensation related to options granted to employees and consultants	-	-	162	-	-	162
Issuance of shares in Business Combination (*) Total comprehensive loss	1,569,403	2	456	122	(2.004)	458
Balance as of June 30, 2022	25,551,906	26	57,048	(284)	(3,904)	(3,782) 7,695

(*) See note 6 a.

	Commo	n stock	Additional paid-in	Accumulated other comprehensive	Accumulated	Total stockholders'
	Number	Amount	capital	loss	deficit	equity
Balance as of January 1, 2021	7,232,836	7	37,164	(424)	(34,671)	2,076
Stock-based compensation related to options granted to employees						
and consultants	-	-	232	-	-	232
Restricted shares issued to shareholder	2,500,000	3	2,615	-	-	2,618
Issuance of shares, net of issuance cost of \$768	4,580,491	4	5,031	-	-	5,035
Exercise of warrants	725,000	1	796	-	-	797
Total comprehensive loss				(16)	(5,797)	(5,813)
Balance as of June 30, 2021	15,038,327	15	45,838	(440)	(40,468)	4,945

	Commo	n stock	Additional paid-in	Accumulated other comprehensive	Accumulated	Total stockholders'
	Number	Amount	capital	loss	deficit	equity
Balance as of April 1, 2022	25,377,528	25	57,000	(348)	(47,379)	9,298
Stock-based compensation related to options granted to employees						
and consultants	-	-	48	-	-	48
Issuance of shares in Business Combination (*)	174,378	1	-	-	-	1
Total comprehensive loss	<u>-</u>	<u>-</u> _		64	(1,716)	(1,652)
Balance as of June 30, 2022	25,551,906	26	57,048	(284)	(49,095)	7,695

(*) See note 6 a.

	Commo	n stock	Additional paid-in	Accumulated other comprehensive	Accumulated	Total stockholders'
	Number	Amount	capital	loss	deficit	equity
Balance as of April 1, 2021	12,145,547	12	42,671	(462)	(36,128)	6,093
Stock-based compensation related to options granted to employees						
and consultants	-	-	89	-	-	89
Restricted shares issued to shareholder	2,500,000	3	2,615	-	-	2,618
Issuance of shares, net of issuance cost of \$32	392,780	*	463	-	-	463
Total comprehensive loss				22	(4,340)	(4,318)
Balance as of June 30, 2021	15,038,327	15	45,838	(440)	(40,468)	4,945

(*) Represents an amount less than \$1

The accompanying notes are an integral part of the interim condensed consolidated financial statements

U.S. dollars in thousands

Six-Months Ended

Cash Bows from operating activities (Journal to Unauditor) Net less (3,904) (5,797) Adjustments to reconcile actions to net cash used in operating activities 7 2 Depociation and amortization of right-of-use asset 20 2 Revaluation of iright-of-use assets 37 1 2 Revaluation of investment in marketable sceurities 11 2 22 Expenses arrising from restricted shares issued to compensate waiver by a shareholder 16 2 23 Expenses arrising from restricted shares issued to compensate waiver by a shareholder 16 2 23 Expenses arrising from restricted shares issued to compensate waiver by a shareholder 16 2 23 Expenses arrising from restricted shares is sweet to compensate waiver by a shareholder 16 2 22 Expenses arrising from restricted shares is sweet to compensate waiver by a shareholder 16 2 2 Decrease (Increase) in other receivables and prepaid expenses 15 2 1 (Decrease) in the decrease in account receivables and prepaid expenses 2 1 2 2 2 2 <th< th=""><th></th><th>June 30</th><th>,</th></th<>		June 30	,
Cash flows from operating activities: (3,904) (5,797) Adjustments to reconcile net loss to net cash used in operating activities: 76 21 Amortization of right-of-uses asset 20 22 Revaluation of dielv-talves asset 37 1 Revaluation of dielv-talves 2,618 2,618 Financing expenses 7 - 2,618 Financing expenses 162 232 (Increase) in account receivables of the proper to the proper of the receivables and prepaid expenses (170 279 (Increase) in account receivables 18 - 1 22 (Increase) in diedered tax liabilities 118 - 1 2 2 (Increase) in account payables 158 - - 1 2 2 4 4 4 1 2 2 4 4 4 2 2		2022	2021
Net loss (3,904) (5,797) Adjustments to reconcile net loss to net cash used in operating activities: 20 21 Depreciation and amoritzation 76 21 Amoritzation of right-of-use asset 20 22 Revaluation of derivatives 37 1 Revaluation of investment in marketable securities 11 (22) Expenses arising from restricted shares issued to compensate waiver by a shareholder - 2,618 Financing expenses 7 - Stock based compensation 162 232 (Increase) in account receivables (55) (7) Decrease (Increase) in other receivables and prepaid expenses (170) 279 (Increase) in other payables 188 - (Decrease) in interaction and int		(Unaudited)	(Unaudited)
Adjustments to reconcile nel loss to net cash used in operating activities: 76 21 Depreciation and amoritzation of right-of-use asset 30 22 Revaluation of derivatives 37 1 Revaluation of of derivatives - 2618 Expenses arrising from restricted shares issued to compensate waiver by a shareholder - 2618 Financing expenses 7 - Stock based compensation 162 232 (flencesse) in account receivables (55) (7) Decrease (Increase) in obter payables (170) 279 (flencesse) in inventory (455) - (flencesse) in interest on their payables (30) (50) (flencesse) in deferred tax liabilities (30) (50) (flencesse) in trade payables (300) (50) (flencesse) in trade payables (300) (50) Increase in account payables (300) (50) (flencesse) in trade payables (300) (50) Net cash used in operating activities (4070) (2.669) Cash flows from investing activi	Cash flows from operating activities:		
Depreciation and amortization 76 21 Amortization of right-of-use asset 20 22 Revaluation of derivatives 37 11 Revaluation of investment in marketable securities 11 (22) Expenses arising from restricted shares issued to compensate waiver by a shareholder - 2,618 Financing expenses 7 - 2,618 Stock based compensation 162 322 (Increase) in account receivables (55) (37) Oberrease (Increase) in other receivables and prepaid expenses (170) 279 (Increase) in in inventory (455) - Increase in in inventory (455) - Increase in account payables (300) (50) Increase in account payables (300) (50) Increase in account payables (300) (50) Net cash used in operating activities (4,070) (2,669) Cash flows from investing activities (300) - Acquisition of a subsidiary, net of eash acquired (300) - Acquisition of a subsidiary, n	Net loss	(3,904)	(5,797)
Amortization of right-of-use asset 20 22 22 22 23 23 3 1 1 (22) 24 24 24 25 26 26 26 26 26 26 26	Adjustments to reconcile net loss to net cash used in operating activities:		
Revaluation of derivatives 37 1 (22) Expenses arising from restricted shares issued to compensate waiver by a shareholder - 2,618 Financing expenses 7 - Stock based compensation 162 2322 (Increase) in account receivables (55) (77) (Increase) in corn receivables and prepaid expenses (170) 279 (Increase) in inventory (455) - (Increase) in inventory (455) - (Increase) in deferred tax liabilities (10) 5 (I) (Decrease) in deferred tax liabilities (10) 5 (I) (Decrease) in trade payables (300) (50) (Increase in account payables (300) (50) (I) (Decrease) in trade payables (300) <td>Depreciation and amortization</td> <td>76</td> <td>21</td>	Depreciation and amortization	76	21
Revaluation of investment in marketable securities 1 (22) Expenses arising from restricted shares issued to compensate waiver by a shareholder - 2,618 Financing expenses 7 - Stock based compensation 162 232 (Increase) in account receivables (55) (77) Decrease (Increase) in other receivables and prepaid expenses (170) 279 (Increase) in inventory (455) - (Increase) in inventory (465) - (Increase) in inventory (465) - (Increase) in indeferred tax hiabilities (300) (50) (Increase) in trade payables (300) (50) Increase in account payables (300) (50) Net cash used in operating activities (4,070) (2,669) Cash flows from investing activities - 184 Port cash provided deposits - 184 Purchase of property and equipment (25) (12) Vet cash provided by (used in) investing activities - 5,035 Proceeds from issuance of shares, net of issua	Amortization of right-of-use asset	20	22
Expenses arising from restricted shares issued to compensate waiver by a shareholder 7	Revaluation of derivatives	37	1
Financing expenses 7 Stock based compensation 162 232 (Increase) in account receivables (55) (37) Observation (170) 279 (Increase) in inventory (485) 2- (Increase in other payables 158 3- (Decrease) in deferred tax liabilities (12) 2- (Decrease) in trade payables (300) (50) Increase in account payables (300) (50) Increase in account payables (4,070) (2,669) Vet cash used in operating activities - 84 Net cash used in operating activities - 184 Purchase of property and equipment (25) (12) Vet cash provided by (used in) investing activities - 5,035 Net cash provided by (used in) investing activities - 5,035 Proceeds from insuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans 18 - Repayment of short-term loans	Revaluation of investment in marketable securities	11	(22)
Stock based compensation 162 232 (Increase) in account receivables (55) (77) (170) (279) (Increase) in inventory (455) (170) (279) (Increase) in inventory (455) (170) (185) (Expenses arising from restricted shares issued to compensate waiver by a shareholder	-	2,618
(Increase) in account receivables (55) (7) Decrease (Increase) in other receivables and prepaid expenses (170) 279 (Increase) in inventory (455) - (Increase) in other payables 158 - (Decrease) in trade payables (300) (50) (Increase in account payables 355 34 Net cash used in operating activities (4,070) (2,669) Cash flows from investing activities (300) - Acquisition of a subsidiary, not of eash acquired (300) - Change in restricted deposits - 184 Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Net cash provided by (used in) investing activities - 5035 Proceeds from issuance of shares, net of issuance costs - 5035 Short term loans 18 - Repayment of long-term loans (27) - Proceeds from Exercise of warrants (27) - Proceeds from Exercise of warrants	Financing expenses	7	-
Decrease (Increase) in other receivables and prepaid expenses (170) (279 (161 crease) in inventory (455) - 1 (161 crease) in inventory (155 crease) in commentary (155 crease) (158 crease) (158 crease) (158 crease) (161 creas	Stock based compensation	162	232
Decrease (Increase) in other receivables and prepaid expenses (170) (279) (Increase) in inventory (455) - 1 (150) (1610) (1510	(Increase) in account receivables	(55)	(7)
Increase in other payables	Decrease (Increase) in other receivables and prepaid expenses	(170)	279
(Decrease) in deferred tax liabilities (12)		(455)	-
Commerciance in account payables (300) (50)	Increase in other payables	158	-
Increase in account payables 355 34 Net cash used in operating activities (4,070) (2,669) Cash flows from investing activities: (300) - Acquisition of a subsidiary, net of cash acquired (300) - Change in restricted deposits - 184 Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: - 5,035 Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans 18 - Repayment of short-term loans 15 - Repayment of short-term loans 12 - Repayment of short-term loans 12 - Repayment of short-term loans 12 - Repayment of short-term loans 207 - Proceeds from Exercise of warrants 207 - Net cash provided by (used in) financing activities 24 5,832	(Decrease) in deferred tax liabilities	(12)	-
Increase in account payables 355 34 Net cash used in operating activities (4,070) (2,669) Cash flows from investing activities: (300) - Acquisition of a subsidiary, net of cash acquired (300) - Change in restricted deposits - 184 Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: - 5,035 Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans 18 - Repayment of short-term loans 15 - Repayment of short-term loans 12 - Repayment of short-term loans 12 - Repayment of short-term loans 12 - Repayment of short-term loans 207 - Proceeds from Exercise of warrants 207 - Net cash provided by (used in) financing activities 24 5,832	(Decrease) in trade payables	(300)	(50)
Cash flows from investing activities: 3000 - Acquisition of a subsidiary, net of cash acquired (300) - Change in restricted deposits - 184 Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: - 5,035 Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans (15) - Repayment of long-term loans (27) - Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 6,725 5,093 Non cash activities:			` /
Cash flows from investing activities: 3000 - Acquisition of a subsidiary, net of cash acquired (300) - Change in restricted deposits - 184 Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: - 5,035 Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans (15) - Repayment of long-term loans (27) - Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 6,725 5,093 Non cash activities:	Net cash used in operating activities	(4 070)	(2,669)
Acquisition of a subsidiary, net of cash acquired (300) - Change in restricted deposits - 184 Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: - 5,035 Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans (15) - Repayment of long-term loans (27) 797 Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093	1 6	(1,070)	(2,009)
Change in restricted deposits 184 Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: - 5,035 Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans (15) - Repayment of long-term loans (27) - Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:			
Purchase of property and equipment (25) (12) Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: - 5,035 Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans (15) - Repayment of long-term loans (27) 797 Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:	Acquisition of a subsidiary, net of cash acquired	(300)	-
Net cash provided by (used in) investing activities (325) 172 Cash flows from financing activities: Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 Repayment of short-term loans (15) Repayment of long-term loans (27) Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:		-	184
Cash flows from financing activities: Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans (15) - Repayment of long-term loans (27) - Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:	Purchase of property and equipment	(25)	(12)
Cash flows from financing activities: Proceeds from issuance of shares, net of issuance costs - 5,035 Short term loans 18 - Repayment of short-term loans (15) - Repayment of long-term loans (27) - Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:	Net cash provided by (used in) investing activities	(325)	172
Proceeds from issuance of shares, net of issuance costs Short term loans Short term loans Repayment of short-term loans Repayment of long-term loans Repayment of long-term loans Proceeds from Exercise of warrants Retain the cash provided by (used in) financing activities Cash provided by (used in) financing activities Cash, cash equivalents and restricted cash (*) Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Non cash activities:		(0.20)	
Short term loans 18			
Repayment of short-term loans (15) - Repayment of long-term loans (27) - Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:	Proceeds from issuance of shares, net of issuance costs	-	5,035
Repayment of long-term loans Proceeds from Exercise of warrants Net cash provided by (used in) financing activities (24) Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) Cash, cash equivalents and restricted cash at the beginning of the period (24) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period (4,218) 3,319 Cash, cash equivalents and restricted cash at the end of the period (5,725 5,093		18	-
Proceeds from Exercise of warrants - 797 Net cash provided by (used in) financing activities (24) 5,832 Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (4,218) 3,319 Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:		(15)	-
Net cash provided by (used in) financing activities Effect of exchange rate fluctuations on cash and cash equivalents Effect of exchange rate fluctuations on cash and cash equivalents Increase (decrease) in cash, cash equivalents and restricted cash (*) Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Annual Cash cash equivalents and restricted cash at the end of the period Cash, cash equivalents and restricted cash at the end of the period On cash activities:		(27)	
Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (218) (23,19) (23,19) (23,19) (24,218) (3,219) (24,218) (3,219) (3,19) (3,19) (3,19) (4,218) (4,218) (4,218) (4,218) (4,218) (5,19) (6,725) (7,19) (7,19) (8,19) (8,19) (8,19) (8,19) (9,19) (9,19) (9,19) (16) (16) (16) (17) (17) (17) (17) (18) (18) (19) (19) (19) (19) (19) (19) (19) (19	Proceeds from Exercise of warrants		797
Effect of exchange rate fluctuations on cash and cash equivalents 201 (16) Increase (decrease) in cash, cash equivalents and restricted cash (*) (218) (23,19) (23,19) (23,19) (24,218) (3,219) (24,218) (3,219) (3,19) (3,19) (3,19) (4,218) (4,218) (4,218) (4,218) (4,218) (5,19) (6,725) (7,19) (7,19) (8,19) (8,19) (8,19) (8,19) (9,19) (9,19) (9,19) (16) (16) (16) (17) (17) (17) (17) (18) (18) (19) (19) (19) (19) (19) (19) (19) (19	Net cash provided by (used in) financing activities	(24)	5,832
Increase (decrease) in cash, cash equivalents and restricted cash (*) Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:			
Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:	Effect of exchange rate fluctuations on cash and cash equivalents	201	(16)
Cash, cash equivalents and restricted cash at the beginning of the period 10,943 1,774 Cash, cash equivalents and restricted cash at the end of the period 6,725 5,093 Non cash activities:	Increase (decrease) in cash, cash equivalents and restricted cash (*)	(4,218)	3,319
Non cash activities:			1,774
Non cash activities:	Cash, cash equivalents and restricted cash at the end of the period	6.725	5 002
	, 1	0,120	3,073
Shares issued in Acquisition of a subsidiary 457 2,618			
	Shares issued in Acquisition of a subsidiary	457	2,618

^{(*) \$4,208} relates to change in cash and cash equivalents and \$10 to change in restricted cash.

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

Note 1 - General

a. My Size, Inc. is developing unique measurement technologies based on algorithms with applications in a variety of areas, from the apparel e-commerce market to the courier services market and to the Do It Yourself smartphone and tablet apps market. The technology is driven by proprietary algorithms which are able to calculate and record measurements in a variety of novel ways.

Following the acquisition of Orgad International Marketing Ltd. ("Orgad") in February 2022 (see note 6), the Company also operates an omnichannel e-commerce platform.

The Company has four subsidiaries, My Size Israel 2014 Ltd ("My Size Israel"), Topspin Medical (Israel) Ltd., and Orgad all of which are incorporated in Israel, and My Size LLC which was incorporated in the Russian Federation. References to the Company include the subsidiaries unless the context indicates otherwise.

b. During the six-month period ended June 30, 2022, the Company has incurred significant losses and negative cash flows from operations and has an accumulated deficit of \$49,095. The Company has financed its operations mainly through fundraising from various investors.

The Company's management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of June 30, 2022, management is of the opinion that its existing cash will be sufficient to fund operations for a period less than 12 months. As a result, there is substantial doubt about the Company's ability to continue as a going concern.

Management's plans include the continued commercialization of the Company's products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations.

The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.

c. In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it spread globally. Many countries around the world, including Israel, have from time to time implemented significant governmental measures to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. While the COVID-19 pandemic did not materially adversely affect the Company's consolidated financial results and operations during the three and six months ended June 30, 2022, the COVID-19 pandemic affected the Company's operations in 2020 and 2021. The pandemic may continue to have an impact on the Company's business, operations, and financial results and conditions, directly and indirectly, including, without limitation, impacts on the health of the Company's management and employees, its operations, marketing and sales activities, and on the overall economy. The extent to which COVID-19 impacts the Company's operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat its impact.

Note 2 - Significant Accounting Policies

a. Unaudited condensed consolidated financial statements:

The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company. In management's opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles ("GAAP") has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2021.

These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2021.

Note 2 - Significant Accounting Policies (cont.)

b. Significant Accounting Policies:

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements, except the following new policies which was adopted following the business combination (see note 6):

1. Inventories

Inventories are measured at the lower of cost or net realizable value. The cost of inventories comprises of the costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business. At the point of the loss recognition, a new, lower-cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

2. Revenue Recognition

Since the acquisition of Orgad (see note 6 - Business combination), the Company's revenues are comprised of two main categories: (1) selling products to customers (2) licensing cloud-enabled software subscriptions, associated software maintenance and support.

Revenue from sale of products

Revenue from sale of products is recognized at the time the related performance obligation is satisfied by transferring a promised good to a customer. Revenue is recognized net of allowances for refunds and any taxes collected from customers, which are subsequently remitted to governmental authorities. Refunds are estimated at contract inception and updated at the end of each reporting period if additional information becomes available. Revenue is recognized when control of the product is transferred to the customer.

The Company maintains a returns policy that allows its customers to return product within a specified period of time. The estimate of the provision for returns is based upon historical experience with actual returns.

Revenue from licensing

The Company recognizes revenue in accordance with ASC Topic 606, Revenues from Contracts with Customers ("ASC 606"). A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party's rights regarding the distinct goods or services to be transferred ("performance obligations"), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.

Note 2 - Significant Accounting Policies (cont.)

Principal versus Agent Considerations

The Company follows the guidance provided in ASC 606 for determining whether it is a principal or an agent in arrangements with customers, by assessing whether the nature of the Company's promise is a performance obligation to provide the specified goods (principal) or to arrange for those goods to be provided by the other party (agent). With regard to products being sold by Orgad through Amazon, this determination involves judgment. The Company determined it is a principal, as it has determined that it controls the promised product before it is transferred to the end customers, it is primarily responsible for fulfilling the promise to provide the goods, and it has discretion in establishing prices. Therefore, the revenues are recorded on a gross basis.

3. Business combinations

The Company applies the provisions of ASC 805, "Business Combination" and allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, the Company estimated the future expected cash flows from acquired platform from a market participant perspective, useful lives and discount rates. In addition, management makes significant estimates and assumptions, which are uncertain, but believed to be reasonable.

Significant estimates in valuing certain intangible assets include but are not limited to future expected cash flows from acquired platforms from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.

Acquisition-related costs are recognized separately from the acquisition and are expensed as incurred.

4. Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Under ASC 350, "Intangible - Goodwill and Other", goodwill is not amortized, but rather is subject to an annual impairment test.

ASC 350 requires goodwill to be tested for impairment at the reporting unit level at least annually, the fourth quarter, or between annual tests in certain circumstances, and written down when impaired. Goodwill is tested for impairment by comparing the fair value of the reporting unit with it carrying value.

ASC 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further impairment testing is required. If it does result in a more likely than not indication of impairment, the two-step impairment test is performed. Goodwill is not deductible for income tax purposes. Goodwill is allocated to the fashion and equipment e-commerce platform segment.

Alternatively, ASC 350 permits an entity to bypass the qualitative assessment for any reporting unit and proceed directly to performing the first step of the goodwill impairment test. There were no impairment charges to goodwill during the period presented.

Note 2 - Significant Accounting Policies (cont.)

5. Intangible assets

Intangible assets consist of identifiable intangible assets that the Company has acquired from previous business combinations. Intangible assets are recorded at costs, net of accumulated amortization. The Company amortizes its intangible assets reflecting the pattern in which the economic benefits of the intangible assets are consumed. When a pattern cannot be reliably determined, the Company uses a straight-line amortization method.

The estimated useful lives of the company's intangible assets are as follows:

Selling Platform 3

Each period the Company evaluates the estimated remaining useful lives of its intangible assets and whether events or changes in circumstances warrant a revision to the remaining period of amortization

c. Use of estimates:

The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.

Note 3 - Financial Instruments

The carrying amounts of cash and cash equivalents, accounts receivable, other receivables, trade payables and accounts payable approximate their fair value due to the short-term maturities of such instruments. In addition, the carrying amounts of a long term loan is approximate to its fair value because there was no change in the market conditions since its exceptions.

The Company holds share certificates in iMine Corporation ("iMine") formerly known as Diamante Minerals, Inc., a publicly traded company on the OTCQB.

Due to sales restrictions on the sale of the iMine shares, the fair value of the shares was measured on the basis of the quoted market price for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the effect of the sales restrictions and is therefore, ranked as Level 2 assets.

		June 30, 2022 Fair value hierarchy	
	Level 1	Level 2	Level 3
Financial assets			
Investment in marketable securities (*)	-	97	-
		June 30, 2022	
		Fair value hierarchy	
	Level 1	Level 2	Level 3
Financial liabilities			
Derivatives	-	39	-
	11		

Note 3 - Financial Instruments (Cont.)

	<u> </u>	December 31, 2021	
	<u></u>	Fair value hierarchy	
	Level 1	Level 2	Level 3
Financial assets			
Investment in marketable securities (*)	-	108	-

(*) For the six and three-month periods ended June 30, 2022 and 2021, the recognized gain (loss) (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was (\$11) and \$3, and \$(22) and \$(27) respectively.

		December 31, 2021				
	<u></u>	Fair value hierarchy				
	Level 1	Level 2	Level 3			
Financial liabilities						
Derivatives	-	2				

Note 4 - Stock Based Compensation

The stock-based expense equity awards recognized in the financial statements for services received is related to Cost of Revenues, Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table:

	Six months e June 30,		Three months ended June 30,		
	2022	2021	2022	2021	
Stock-based compensation expense – Cost of revenues	28	-	7	-	
Stock-based compensation expense - Research and					
development	18	70	6	9	
Stock-based compensation expense - Sales and marketing	58	93	19	68	
Stock-based compensation expense - General and					
administrative	58	69	16	12	
			_		
	162	232	48	89	

Options issued to consultants:

In July 2019, the Company entered into a three-year agreement with a consultant ("Consultant14") to provide services to the Company including assisting the Company to promote, market and sell the Company's technology to potential customers. Pursuant to such agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant14 options to purchase up to 2,667 shares of the Company's common stock upon execution of the agreement. The options are exercisable at \$15.00 per share and shall vest in 3 equal instalments every twelve months starting July 2019. Unexercised options shall expire 4 years from the effective date.

Note 4 - Stock Based Compensation (Cont.)

In addition, the Company agreed to issue to Consultant14 options to purchase up to 22,233 shares of the Company's common stock upon execution of the agreement. The options are exercisable at \$1.08 per share and shall vest in 4 equal instalments every six months starting September 2020. Unexercised options shall expire 5 years from the effective date.

During the six and three-month period ended June 30,2022 and 2021, an amount of \$7 and \$4, and \$7 and \$4 respectively, were recorded by the Company as stock-based equity awards with respect to Consultants.

Stock Option Plan for Employees:

In March 2017, the Company adopted the My Size, Inc. 2017 Equity Incentive Plan (the "2017 Employee Plan") pursuant to which the Company's Board of Directors may grant stock options to officers and key employees. The total number of options which may be granted to directors, officers, employees under this plan, is limited to 5,770,000 options. Stock options can be granted with an exercise price equal to or less than the stock's fair market value at the date of grant.

On May 25, 2020, the compensation committee of the Board of Directors of the Company reduced the exercise price of outstanding options of employees and directors of the Company for the purchase of an aggregate of 140,237 shares of common stock of the Company (with exercise prices ranging between \$18.15 and \$9.15) to \$1.04 per share, which was the closing price for the Company's common stock on May 22, 2020, and extended the term of the foregoing options for an additional one year from the original date of expiration. The incremental compensation cost resulting from the repricing was \$53, and the expenses during the six-month period ended June 30, 2022 and 2021 were \$2 and \$1, respectively and the expenses during the three months ended June 30, 2022 and 2021 were \$47 and \$53, respectively.

On August 10, 2020, the Company's shareholders approved an increase in the shares available for issuance under the 2017 Employee Plan from 200,000 to 1,450,000 shares. As a result, and pursuant to approval of the Company's compensation committee that was contingent on the foregoing shareholder approval, the number of shares available for issuance under the Company's 2017 Consultant Incentive Plan was reduced from 466,667 to 216,667 shares. On December 30, 2021, the Company's shareholders approved an increase in the shares available for issuance under the 2017 Equity Incentive Plan from 1,450,000 shares to 5,770,000 shares.

During the six and three-month period ended June 30, 2022, the Company did not grant any stock options under the 2017 Employee Plan, no options were exercised and options to purchase 51,873 shares of common stock, expired.

The total stock option compensation expense during the six and three-month period ended June 30, 2022 and 2021 which was recorded was \$44 and \$171, and \$15 and \$103, respectively.

Note 5 - Contingencies and Commitments

a. On August 7, 2018, the Company commenced an action against North Empire LLC ("North Empire") in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement (the "Agreement") in which it is seeking damages in an amount to be determined at trial, but in no event less than \$616 thousands. On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of \$11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of \$10,958,589. North Empire also filed a third-party complaint against the Company's CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire's counterclaims. On November 15, 2018, the Company's CEO and now former Chairman of the Board filed a motion to dismiss North Empire's third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. Discovery has been completed and both parties have filed motions for summary judgment in connection with the claims and counterclaims. On December 30, 2021, the Court denied both My Size and North Empire's motions for summary judgment, arguing there were factual issues to be determined at trial. On January 26, 2022, the Company filed a notice of appeal of the summary judgment decision. The appeal must be fully perfected and filed by September 24, 2022. On February 3, 2022, the Company filed a motion to reargue the Court's decision denying the Company's motion for summary judgment. On or about March 31, 2022, N

The Company believes it is more likely than not that the counterclaims will be denied.

b. On July 5, 2021, the Company was served with a legal complaint filed by Fidelity Venture Capital Ltd. and Dror Atzmon in the Magistrate's Court in Tel Aviv for a monetary award in an amount of NIS 1,436,679 (approximately \$450) and a declaratory relief. The plaintiffs allege that the Company breached its contractual obligations to pay them for services allegedly rendered to the Company by the plaintiffs under a certain consulting agreement dated July 2, 2014, in an amount of NIS 819,000 (approximately \$256). Additionally, the plaintiffs allege that the Company should compensate them for losses allegedly incurred by them following their investment in the Company's shares issued under a certain private offering. In the alternative, the plaintiffs move that the court will declare the investment agreement void with full restitution of plaintiffs' original investment in an amount of NIS 1,329,650 (approximately \$415). The Company filed its statement of defense on October 25, 2021. The first court preliminary hearing was held on March 1, 2022. Following the first preliminary hearing and the Court's comments and recommendation, the plaintiffs filed a motion to strike out the claim without prejudice. On March 8, 2022 the Court ordered dismissal without prejudice of the claim. The Court also ruled that to the extent the plaintiffs will not move within 7 days to revise their motion do dismiss their claim "with prejudice", the Company will be entitled to request an order for costs. On April 11, 2022 the Court ordered the plaintiffs to pay the Company's costs in the amount of NIS 15,000, within 30 days.

Note 6 - Business Combination

Acquisition of Orgad

On February 7, 2022, the Company acquired 100% of the shares and voting interests in Orgad an omnichannel e-commerce platform. The acquisition was designed to create an additional revenue stream for the Company by becoming a direct e-commerce seller while leveraging the synergies between MySizeID and Orgad's e-commerce platform.

The results of operations of Orgad have been included in the consolidated financial statements since the acquisition date of February 7, 2022. Orgad revenues included in the Company's consolidated statement of operations from February 7, 2022 through June 30, 2022 were \$1,112 and for the three-month period ended June 30, 2022 were \$752. If the acquisition had occurred on January 1, 2021, management estimates that the consolidated pro forma revenues for the year would have been \$2,768, and the net loss would have been \$2,272.

(a) Consideration transferred

The following table summarizes the acquisition date fair value of each major class of consideration:

	USD	
	Thousands	
Cash (*)		300
Issuance of shares of common stock (1,395,025 shares) (**)		457
Total consideration transferred		757

(*) The cash payment is subject to working capital adjustments.

(**) Quoted price as of acquisition date

In addition, the Company agreed to pay to the former owners of Orgad, on the two-year and the three-year anniversary of the closing, \$350,000 in each of these years provided that in the case of the second and third instalments certain revenue targets are met and subject further to certain downward post-closing adjustment. Furthermore, 1,395,024 shares of common stock will be issued in eight equal quarterly instalments until the lapse of two years from closing. Additional earn-out payments of 10% of the operating profit of Orgad for the years 2022 and 2023 will also be paid. All of these payments are subject to the former owners being actively engaged with Orgad at the date such payment is due, and therefore were not taken as part of the consideration for the business combination.

During the six and three-month period ended June 30, 2022 an amount of \$111 and \$28 was recorded in respect of the cash instalments respectively, and \$127 and \$54 in respect of stocks issuance, respectively.

(b) Identifiable assets acquired and liabilities assumed

Under the preliminary purchase price allocation, the Company allocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on the preliminary estimates of their fair values, which were determined using generally accepted valuation techniques based on estimates and assumptions made by management at the time of the acquisition. Such estimates are subject to change during the measurement period which is not expected to exceed one year. The purchase price allocation was not finalized duo to examination of the net working capital of Orgad at the acquisition date. Any adjustments to the preliminary purchase price allocation identified during the measurement period will be recognized in the period in which the adjustments are determined.

Note 6 - Business Combination (Cont.)

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:

	Thousands USD
Cash and Cash Equivalent	0
Trade receivables	89
Other receivables	239
Inventory	864
Fixed assets	55
Long-term deposits	31
Selling platform (*)	378
Goodwill	268
Short-term credit	(181)
Trade payables	(660)
Other payables	(101)
Long-term loan	(138)
Deferred Taxes	(87)
Total net assets acquired	757

(*) The estimated useful lives of the selling platform are three years. During the six and three-month period ended June 30,2022 an amount of \$52 and \$32 was recorded in respect of amortization expenses.

(c) Acquisition-related costs

The Company incurred transaction costs of approximately \$55 and none during the six-month and three-month period ended June 31, 2022 which were included in general and administrative expenses in the consolidated statements of income (loss), (the total amount recorded during the first quarter of the year).

Note 7 – Operating Segments

As a result of the business combination in the reporting period (see note 6), the company has two reportable segments: (i) fashion and equipment e-commerce platform and (ii) SaaS based innovative artificial intelligence driven measurement solutions. The fashion and equipment e-commerce platform which represent Orgad's activity that was acquired by the Company, mainly operates on Amazon. The SaaS based innovative artificial intelligence driven measurement solutions, or SaaS Solutions operating segment consists of My Size Inc and My Size Israel.

Information related to the operations of the Company's reportable operating segments is set forth below:

	Fashion and equipment e-commerce platform	SaaS Solutions	Total	
For the six months ended June 30, 2022				
Revenue	1,112	2 93	3	1,205
Operating (loss) income	71	(3,82)	8)	(3,757)
For the three months ended June 30, 2022				
Revenue	752	2 49	9	801
Operating (loss) income	(2	2) (1,650	0)	(1,652)
	6	Fashion and equipment e-commerce platform	SaaS Solutions	
For June 30, 2022:				
Assets		1,860		8,806

Note 8 - Subsequent events

In July 2022, Amazon deactivated Orgad's Amazon U.S. store as a result of complaints submitted due to an error in the listed manufacturer of certain products on Orgad's store. Orgad resolved the complaints and is presently in the process of having its account reinstated.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis provide information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read together with our condensed consolidated interim financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 31, 2022, or the Annual Report, including the consolidated annual financial statements as of December 31, 2021, and their accompanying notes included therein.

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan" and "would." For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Quarterly Report on Form 10-Q. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to:

- our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;
- our ability to continue as a going concern;
- risks related to the COVID-19 pandemic;
- the new and unproven nature of the measurement technology markets;
- our ability to achieve customer adoption of our products;
- our dependence on assets we purchased from a related party and the risk that such assets may in the future be repurchased;
- our ability to enhance our brand and increase market awareness;
- our ability to introduce new products and continually enhance our product offerings;
- the success of our strategic relationships with third parties;
- information technology system failures or breaches of our network security;
- $\bullet \quad \textit{competition from competitors;}$
- our reliance on key members of our management team;
- current or future litigation; and
- the impact of the political and security situation in Israel on our business.

The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to the Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors referred to on page 12 of our Annual Report, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Unless the context otherwise requires, all references to "we," "us," "our" or "the Company" in this Quarterly Report on Form 10-Q are to My Size, Inc. a Delaware corporation, and its subsidiaries, including MySize Israel 2014 Ltd, Topspin Medical (Israel) Ltd, Orgad International Marketing Ltd., or Orgad and My Size LLC. taken as a whole.

Overview

We are a creator of mobile device measurement solutions that has developed innovative solutions designed to address shortcomings in multiple verticals, including the e-commerce fashion/apparel, shipping/parcel and do it yourself, or DIY, industries. Utilizing our sophisticated algorithms within our proprietary technology, we can calculate and record measurements in a variety of novel ways, and most importantly, increase revenue for businesses across the globe.

Our solutions can be utilized to accurately take measurements of a variety of items via a mobile device. By downloading the application to a smartphone, the user is then able to run the mobile device over the surface of an item the user wishes to measure. The information is then automatically sent to a cloud-based server where the dimensions are calculated through our proprietary algorithms, and the accurate measurements (+ or - 2 centimeters) are then sent back to the user's mobile device. We believe that the commercial applications for this technology are significant in many areas.

Currently, we are mainly focusing on the e-commerce fashion/apparel industry. In addition, our solutions address the shipping/parcel and DIY uses markets.

While we rollout our products to major retailers and apparel companies, there is a lead time for new customers to ramp up before we can recognize revenue. This lead time varies between customers, especially when the customer is a tier 1 retailer, where the integration process may take longer. Generally, first we integrate our product into a customer's online platform, which is followed by piloting and implementation, and, assuming we are successful, commercial roll-out, all of which takes time before we expect it to impact our financial results in a meaningful way. While we have begun generating initial sales revenue, we do not expect to generate meaningful revenue during the upcoming quarters. Because of the numerous risks and uncertainties associated with the success of our market penetration and our dependence on the extent to which MySizeID is adopted and utilized, we are unable to predict the extent to which we will recognize revenue. We may be unable to successfully develop or market any of our current or proposed products or technologies, those products or technologies may not generate any revenues, and any revenues generated may not be sufficient for us to become profitable or thereafter maintain profitability.

Orgad Acquisition

On February 7, 2022, My Size Israel 2014 Ltd, or My Size Israel, entered into a Share Purchase Agreement, or the Orgad Agreement, with Amar Guy Shalom and Elad Bretfeld, or the Orgad Sellers, pursuant to which the Orgad Sellers agreed to sell to My Size Israel all of the issued and outstanding equity of Orgad.

Orgad operates an omnichannel e-commerce platform engaged in online retailing in the global market. It operates as a third-party seller on Amazon.com, eBay and others. Orgad currently manages more than 1,000 stock-keeping units, or SKUs, mainly in fashion, apparel and shoes, but is capable of managing tens of thousands of SKUs.

The Orgad Sellers are the sole title and beneficial owners of 100% of the shares of Orgad. In consideration of the shares of Orgad, the Orgad Sellers are entitled to receive (i) up to \$1,000,000 in cash, or the Orgad Cash Consideration, (ii) an aggregate of 2,790,049 shares, or the Orgad Equity Consideration, of our common stock, and (iii) earn-out payments of 10% of the operating profit of Orgad for the years 2022 and 2023. The transaction closed on the same day.

The Orgad Cash Consideration is payable to the Orgad Sellers in three installments, according to the following payment schedule: (i) \$300,000 which we paid upon closing, (ii) \$350,000 payable on the two-year anniversary of the closing, and (iii) \$350,000 payable on the three-year anniversary of the closing, provided that in the case of the second and third installments certain revenue targets are met and subject further to certain downward post-closing adjustment.

The Equity Consideration is payable to the Orgad Sellers according to the following payment schedule: (i) 1,395,025 shares were issued at closing, and (ii) 1,395,024 shares will be issued in eight equal quarterly installments until the lapse of two years from closing, subject to certain downward post-closing adjustment.

The payment of the second and third cash installments, the equity installments and the earn out are further subject in each case to the Orgad Sellers being actively engaged with Orgad at the date such payment is due (except if the Orgad Sellers resign due to reasons relating to material reduction of salary or adverse change in their position with Orgad or its affiliates).

In connection with the Orgad Agreement, each of the Orgad Sellers entered into employment agreements with Orgad and six-month lock-up agreements with us.

Operations in Russia

In addition to our Israel operations, we have operations in Russia through our wholly owned subsidiary, My Size LLC. Specifically, we undertake some of our sales and marketing using personnel located in Russia. To date, the invasion of Ukraine by Russia has not had a material impact on our business.

Results of Operations

The table below provides our results of operations for the periods indicated.

	 Three mo Jun	nths e 30		 Six mont June		ded
	2022		2021	2022		2021
	(dollars in	thou	isands)	(dollars in t	hous	ands)
Revenues	\$ 801	\$	30	\$ 1,205	\$	57
Cost of revenues	(479)		-	(730)		-
Gross profit	322		30	475		57
Research and development expenses	(390)		(3,007)	(802)		(3,380)
Sales and marketing	(895)		(731)	(1,854)		(1,277)
General and administrative	(689)		(605)	(1,576)		(1,229)
Operating loss	(1,652)		(4,313)	(3,757)		(5,829)
Financial income (expenses), net	(64)		(27)	 (147)		32
Net loss	\$ (1,716)	\$	(4,340)	\$ (3,904)	\$	(5,797)

Six and Three Months Ended June 30, 2022 Compared to Six and Three Months Ended June 31, 2021

Revenues

We started to generate revenue in 2019 and we expect to incur additional losses to increase our sales and marketing efforts and to perform further research and development activities. Our revenues for the six months ended June 30, 2022 amounted to \$1,205,000 compared to \$57,000 for the six months ended June 30, 2021. Our revenues for the three months ended June 30, 2022 amounted to \$801,000 compared to \$30,000 for the three months ended June 30, 2021. The increase was primarily attributable to \$1,112,000 in revenue generated from Orgad from February 7, 2022, the the date of closing of the Orgad acquisition, or the Acquisition Date, through to the end of the second quarter 2022 and to \$752,000 in revenue generated from Orgad for the three months ended June 30, 2022.

Cost Of Revenues

Our cost of revenues expenses for the six and three months ended June 30, 2022 amounted to \$730,000 and \$479,000, respectively, compared to none for the six and three months ended June 30, 2021. The increase in comparison with the corresponding period was due to the cost of goods of the revenues generated from Orgad's operations.

Research and Development Expenses

Our research and development expenses for the six months ended June 30, 2022 amounted to \$802,000 compared to \$3,380,000 for the six months ended June 30, 2021. The decrease in comparison with the corresponding period primarily resulted from share-based payment in the amount of \$2,618,000 that was recorded in the corresponding period attributed to the share issuance to Shoshana Zigdon under the Amendment to Purchase Agreement dated May 26, 2021, and decrease in shared based expenses to employees.

Our research and development expenses for the three months ended June 30, 2022 amounted to \$390,000 compared to \$3,007,000 for the three months ended June 30, 2021. The decrease in comparison with the corresponding period primarily resulted from share-based payment in amount of \$2,618,000 that was recorded in the corresponding period attributed to the share issuance to Shoshana Zigdon under the Amendment to Purchase Agreement dated May 26, 2021 and decrease in shared based expenses to employees.

Sales and Marketing Expenses

Our sales and marketing expenses for the six months ended June 30, 2022 amounted to \$1,854,000 compared to \$1,277,000 for the six months ended June 30, 2021. The increase in comparison with the corresponding period was mainly due to the hiring of new employees and expenses associated with Orgad activities, offset by a reduction in share-based payment expenses to employees and consultants.

Our sales and marketing expenses for the three months ended June 30, 2022 amounted to \$895,000 compared to \$731,000 for the three months ended June 30, 2021. The increase in comparison with the corresponding period was mainly due to expenses associated with Orgad activities, offset by a reduction in share-based payment expenses to employees and consultants.

General and Administrative Expenses

Our general and administrative expenses for the six months ended June 30, 2022 amounted to \$1,576,000 compared to \$1,229,000 for the six months ended June 30, 2021. The increase in comparison with the corresponding period was mainly due to professional services attributed to the Orgad acquisition expenses associated with Orgad activities.

Our general and administrative expenses for the three months ended June 30, 2022 amounted to \$689,000 compared to \$605,000 for the three months ended June 30, 2021. The increase in comparison with the corresponding period was mainly due to professional services attributed to the Orgad expenses associated with Orgad activities.

Operating Loss

As a result of the foregoing, for the six months ended June 30, 2022, our operating loss was \$3,757,000 a decrease of \$2,072,000 compared to our operating loss for the six months ended June 30, 2021 of \$5,829,000.

As a result of the foregoing, for the three months ended June 30, 2022, our operating loss was \$1,652,000 a decrease of \$2,661,000 compared to our operating loss for the three months ended June 30, 2021 of \$4,313,000.

Financial Income (Expenses), Net

Our financial expense, net for the six months ended June 30, 2022 amounted to \$147,000 compared to financial income of \$32,000 for the six months ended June 30, 2021. During the six months ended June 30, 2022, we had financial expenses mainly from exchange rate differences and revaluation of investment in marketable securities whereas in the corresponding period we had financial income primarily due revaluation of investment in marketable securities.

Our financial expense, net for the three months ended June 30, 2022 amounted to \$64,000 compared to financial expenses of \$27,000 for the three months ended June 30, 2021. During the three months ended June 30, 2022, we had financial expenses mainly from exchange rate differences and revaluation of investment in marketable securities whereas in the corresponding period we had financial expenses primarily due revaluation of investment in marketable securities and exchange rate differences offset in income from revaluation of derivative.

Net Loss

As a result of the foregoing, our net loss for the six months ended June 30, 2022 was \$3,904,000, compared to net loss of \$5,797,000 for the six months ended June 30, 2021. The decrease in the net loss was mainly due to the reasons mentioned above.

As a result of the foregoing, our net loss for the three months ended June 30, 2022 was \$1,716,000, compared to net loss of \$4,340,000 for the three months ended June 30, 2021. The decrease in the net loss was mainly due to the reasons mentioned above.

Liquidity and Capital Resources

Since our inception, we have funded our operations primarily through public and private offerings of debt and equity in the State of Israel and in the U.S.

As of June 30, 2022, we had cash, cash equivalents, and restricted cash of \$6,725,000 compared to \$10,943,000 of cash, cash equivalents and restricted cash as of December 31, 2021. This decrease primarily resulted from our operating activities, the acquisition of Orgad, and resources that were deployed to grow Orgad's business.

Cash used in operating activities amounted to \$4,070,000 for the six months ended June 30, 2022, compared to \$2,669,000 for the six months ended June 30, 2021. The increase in cash used in operating activities was mainly due to the acquisition of Orgad and working capital.

Net cash used in investing activities was \$325,000 for the six months ended June 30, 2022, compared to cash provided by investing activities of \$172,000 for the six months ended June 30, 2021. The increase from the corresponding period was mainly due to the acquisition of Orgad offset by changes in restricted deposits that occured in the six months ended June 30, 2021.

Net cash used in financing activities was \$24,000 for the six months ended June 30, 2021, compared to cash provided by financing activities of \$5,832,000 for the six months ended June 30, 2021. The cash flow from financing activities for the six months ended June 30, 2021 resulted from the public offerings that occurred in January 2021 and March 2021 and from proceeds that were received from an investor for warrants that were exercised.

We do not have any material commitments for capital expenditures during the next twelve months.

We expect that we will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of June 30, 2022, we believe our existing cash will be sufficient to fund operations for a period less than 12 months. As a result, there is substantial doubt about our ability to continue as a going concern. We will need to raise additional capital, which may not be available on reasonable terms or at all. Additional capital would be used to accomplish the following:

- finance our current operating expenses;
- pursue growth opportunities;
- · hire and retain qualified management and key employees;
- respond to competitive pressures;
- · comply with regulatory requirements; and
- · maintain compliance with applicable laws.

Current conditions in the capital markets are such that traditional sources of capital may not be available to us when needed or may be available only on unfavorable terms. Our ability to raise additional capital, if needed, will depend on conditions in the capital markets, economic conditions, the impact of the COVID-19 pandemic, the Russian invasion of Ukraine, and a number of other factors, many of which are outside our control, and on our financial performance. Accordingly, we cannot assure you that we will be able to successfully raise additional capital at all or on terms that are acceptable to us. If we cannot raise additional capital when needed, it may have a material adverse effect on our business, results of operations and financial condition.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities could result in substantial dilution for our current stockholders. The terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities thenoutstanding. We may issue additional shares of our common stock or securities convertible into or exchangeable or exercisable for our common stock in connection with hiring or retaining personnel, option or warrant exercises, future acquisitions or future placements of our securities for capital-raising or other business purposes. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline and existing stockholders may not agree with our financing plans or the terms of such financings. In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition. Furthermore, any additional debt or equity financing that we may need may not be available on terms favorable to us, or at all. If we are unable to obtain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, or we may have to cease our operations, which would have a material adverse effect on our business, results of operations and financial condition.

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

Critical Accounting Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles issued by the Financial Accounting Standards Board, or FASB. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies were revenue from contracts with customers which are more fully described in the notes to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. We believe that these accounting policies discussed are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management's estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.

Item 3. Quantitative and Qualitative Disclosure About Market Risk.

Not required for a smaller reporting company.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2022. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of June 30, 2022 were effective.

Our Chief Executive Officer and Chief Financial Officer do not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Changes in Internal Controls

During the most recent fiscal quarter, no change has occurred in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II - Other Information

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

North Empire LLC

On August 7, 2018, we commenced an action against North Empire LLC ("North Empire") in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement (the "Agreement") in which we are seeking damages in an amount to be determined at trial, but in no event less than \$616,000. On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of \$11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by us against them, alleging that we failed to deliver stock certificates to North Empire also filed a third-party complaint against our CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, we filed a reply to North Empire's counterclaims. On November 15, 2018, our CEO and now former Chairman of the Board filed a motion to dismiss North Empire's third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. Discovery has been completed and both parties have filed motions for summary judgment in connection with the claims and counterclaims. On December 30, 2021, the Court denied both My Size and North Empire's motions for summary judgment, arguing there were factual issues to be determined at trial. On January 26, 2022, we filed a notice of appeal of the summary judgment decision. The appeal must be fully perfected and filed by July 26, 2022. On February 3, 2022, we filed a motion to reargue the Court's decision denying our motion for summary judgment. On or about March 31, 2022, North Empire filed its opposition papers to our motion to reargue. On or about May 20, 2022, we filed our reply papers, in further support of its motion to reargue. That mo

Item 1A. Risk Factors.

Except for the Risk Factors included in our previous filings made with the SEC and as set forth below, there have been no material changes to our risk factors from those disclosed in "Part I. Item 1A. Risk Factors" in the Form 10-K filed with the SEC on March 18, 2022.

A significant majority of Orgad's revenue is from sales of products on Amazon's U.S. Marketplace and any change, limitation or restriction on our ability to operate on Amazon's platform or any other marketplace could have a material adverse impact to our business, results of operations, financial condition and prospects.

Orgad, our wholly owned subsidiary, operates an omnichannel e-commerce platform engaged in online retailing in the global market. It operates as a third-party seller on Amazon.com, eBay and others. A substantial percentage of Orgad's revenue is driven by sales on Amazon's U.S. marketplace and Orgad is subject to terms of service of Amazon and other maketplaces and various other seller policies and services that apply to third parties selling products on Amazon and other marketplaces. Generally, a marketplace has the right to terminate or suspend its agreement with Orgad at any time and for any reason. Such marketplace may take other actions against Orgad such as suspending or terminating a seller account or product listing and withholding payments owed to Orgad indefinitely. For example, in July 2022, Amazon deactivated Orgad's Amazon U.S. store as a result of complaints submitted due to an error in the listed manufacturer of certain products on Orgad's store. Orgad is in the process of having its account reinstated however if the deactivation were to continue for a prolonged period of time, or if Amazon were to terminate Orgad's account, this would have a material adverse effect on our business, results of operations, financial condition and prospects. While Orgad endeavors to materially comply with the terms of services of the marketplaces on which it operates, we can provide no assurance that these marketplaces will have the same determination with respect to our compliance.

In addition, Amazon and other marketplaces can make changes to its platform that could require Orgad to change the manner in which it operates, limit its ability to successfully launch new products or increase its costs to operate and such changes could have an adverse effect on our business, results of operations, financial condition and prospects. Examples of changes that could impact us relate to platform fee charges (i.e., selling commissions), exclusivity, inventory warehouse availability, excluded products and limitations on sales and marketing. Any change, limitation or restriction on our ability to sell on Amazon's platform or any other marketplace, even if temporary, could have a material impact on our business, results of operations, financial condition and prospects.

Orgad also relies on services provided by Amazon's fulfillment platform, including Prime Certification, which provides for expedited shipping to the consumer, an important aspect in the buying decision for consumers. For products that Orgad fulfills itself, Orgad is qualified to offer our products for sale with Prime Certification delivery. Any inability to market our products for sale with expedited delivery provided under Prime Certification could have a material impact on our business, results of operations, financial condition and prospects. Failure to remain compliant with the best fulfillment practices on Amazon's platform could have a material impact on our business, results of operations, financial condition and prospects. In addition, due to the COVID-19 pandemic, Amazon has changed the amount of inventory it accepts per product for a period of time. If this were to continue it could cause us to miss sales and/or pay additional shipping costs which would harm our business operations and financial conditions.

Orgad's business depends on its ability to build and maintain strong product listings on e-commerce platforms. Orgad may not be able to maintain and enhance our product listings if it receives unfavorable customer complaints, negative publicity or otherwise fails to live up to consumers' expectations, which could materially adversely affect our business, results of operations and growth prospects.

Maintaining and enhancing Orgad's product listings is critical in expanding and growing its business. However, a significant portion of Orgad's perceived performance to the customer depends on third parties outside of its control, including suppliers and third-party delivery agents as well as online retailers such as Amazon and eBay. Because Orgad's agreements with its online retail partners are generally terminable at will, it may be unable to maintain these relationships, and our results of operations could fluctuate significantly from period to period. Because Orgad relies on third parties to deliver its products, it is subject to shipping delays or disruptions caused by inclement weather, natural disasters, labor activism, health epidemics or bioterrorism. It may also experience shipping delays or disruptions due to other carrier-related issues relating to their own internal operational capabilities. Further, Orgad relies on the business continuity plans of these third parties to operate during pandemics, like the COVID-19 pandemic, and it has limited ability to influence their plans, prevent delays, and/or cost increases due to reduced availability and capacity and increased required safety measures.

Customer complaints or negative publicity about its products, delivery times, or marketing strategies, even if not accurate, especially on blogs, social media websites and third-party market sites, could rapidly and severely diminish consumer view of Orgad's product listings and result in harm to its brand. Customers may also make safety-related or other types of claims regarding products sold through our online retail partners, such as Amazon, which may result in an online retail partner removing the product from its marketplace. We also use and rely on other services from third parties, such as our telecommunications services, and those services may be subject to outages and interruptions that are not within our control.

Orgad faces risks related to successfully optimizing and operating its fulfillment and customer service operations.

Failures to adequately predict customer demand or otherwise optimize and operate its fulfillment and customer service operations successfully from time to time result in excess or insufficient fulfillment or customer service capacity, increased costs, and impairment charges, any of which could materially harm our business. As Orgad continues to add fulfillment and customer service capability or add new businesses with different requirements, its fulfillment and customer service operations become increasingly complex and operating them becomes more challenging. There can be no assurance that Orgad will be able to operate our operations effectively.

In addition, failure to optimize inventory in our fulfillment operations increases net shipping cost by requiring long-zone or partial shipments. Orgad may be unable to adequately staff its fulfillment and customer service operations. Orgad's failure to properly handle such inventory or to accurately forecast product demand may result in it being unable to secure sufficient storage space or to optimize its fulfillment operations or cause other unexpected costs and other harm to our business and reputation.

Orgad relies on a limited number of shipping companies to deliver inventory to it and completed orders to our customers. The inability to negotiate acceptable terms with these companies or performance problems or other difficulties experienced by these companies could negatively impact our operating results and customer experience. In addition, Orgad's ability to receive inbound inventory efficiently and ship completed orders to customers also may be negatively affected by natural or man-made disasters, extreme weather, geopolitical events and security issues, labor or trade disputes, and similar events.

The variability in Orgad's retail business places increased strain on its operations.

Demand for Orgad's product listings can fluctuate significantly for many reasons, including as a result of seasonality, promotions, product launches, or unforeseeable events, such as in response to natural or man-made disasters, extreme weather, or geopolitical events. For example, Orgad expects a disproportionate amount of our retail sales to occur during our fourth quarter. Failure to stock or restock popular products in sufficient amounts such that Orgad fails to meet customer demand could significantly affect our revenue and our future growth. If too many customers access the websites on which Orgad engages in online retailing within a short period of time due to increased demand, Orgad may experience system interruptions that make the websites unavailable or prevent us from efficiently fulfilling orders, which may reduce the volume of goods its offers or sell and the attractiveness of its products. In addition, Orgad may be unable to adequately staff for fulfillment of orders and customer service during these peak periods and delivery and other fulfillment companies and customer service co-sourcers may be unable to meet the seasonal demand.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit

Description of Exhibits
Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Inline XBRL Instance Document
Inline XBRL Taxonomy Schema
Inline XBRL Taxonomy Calculation Linkbase
Inline XBRL Taxonomy Definition Linkbase
Inline XBRL Taxonomy Label Linkbase
Inline XBRL Taxonomy Presentation Linkbase
Cover Page Interactive Data File (formatted as Inline XBRL document and contained in Exhibit 101)

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

My Size, Inc.

Date: August 15, 2022 By: /s/Ronen Luzon

Ronen Luzon

Chief Executive Officer (Principal Executive Officer)

By: /s/ Or Kles Or Kles Date: August 15, 2022

Chief Financial Officer (Principal Financial and Accounting Officer)

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

I, Ronen Luzon certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of My Size, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:
 - c. Evaluated the effectiveness of the registrant's disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 15, 2022 By: /s/Ronen Luzon

Ronen Luzon Chief Executive Officer (Principal Executive Officer)

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

I, Or Kles, certify that:

- 1 I have reviewed this Quarterly Report on Form 10-Q of My Size, Inc.;
- 2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:
 - c. Evaluated the effectiveness of the registrant's disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 15, 2022 By: /s/ Or Kles

Or Kles

Chief Financial Officer

(Principal Financial and Accounting Officer)

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of My Size, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ronen Luzon, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Company's Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 15, 2022

By: /s/Ronen Luzon

Ronen Luzon Chief Executive Officer (Principal Executive Officer)

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of My Size, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Or Kles, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Company's Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 15, 2022

By: /s/ Or Kles

Or Kles

Chief Financial Officer

(Principal Financial and Accounting Officer)